2.0900 -0.06 (-2.79%)
After hours: 5:05PM EDT
|Bid||2.0500 x 1100|
|Ask||2.1500 x 1400|
|Day's Range||1.9900 - 2.2500|
|52 Week Range||0.3500 - 4.7650|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 17, 2020 - May 21, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.80|
Over the last month, shares of micro-cap biotech Agile Therapeutics (AGRX) have crashed by an alarming 55%. Following such a remarkable decline, you would think the company must be in real trouble, but not so, says one analyst.Maxim’s Jason McCarthy argues that not only does the pullback set up an “attractive entry point,” if you take a deeper look at the company’s finances and catalysts, there’s a very attractive opportunity at play.Although volatility currently reigns supreme across the board, since the turn of the year, AGRX has been on a unique rollercoaster ride. Less than six weeks ago, Agile’s share price was on the rise following the FDA’s approval of Twirla, the company’s contraceptive patch. As it stands, the plan to launch Twirla in Q4 still remains on track. So far, there have been no delays from manufacturing partner Corium.Additionally, McCarthy notes, after recent measures, Agile has a very healthy balance sheet. In February, Agile secured a loan deal from Perceptive Advisors, for $35 million, which is interest free until 2023. Also last month, Agile raised an additional $48 million from equity financing.McCarthy said, “YE-19 cash was $34.5M. Remember, that alone would have likely gotten the company through 2020. However, when we combine the loan from Perceptive, use of the ATM and the $48M in net proceeds from the 2/21 equity financing, Agile should have ~$100M in cash. With Twirla launching later this year, there should be at least 2 years of runway, possibly longer depending on the launch trajectory.”Based on the combination of an approved drug, a strong balance sheet and favorable timelines to “weather the COVID-19 storm,” the analyst rates Agile as a “top pick in our coverage universe.”Therefore, McCarthy reiterates a Buy rating on Agile along with a $8 price target. The implication for investors? Possible upside of a sky scraping 406%. (To watch McCarthy’s track record, click here)The Street agrees. Agile’s Strong Buy consensus rating breaks down into solely Buy ratings – 5, in fact. The average price target comes in identical to McCarthy’s, at $8.00. (See Agile stock analysis on TipRanks)
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
Cheap stocks - that is, really cheap stocks that trade for single-digit prices - are among the most divisive stocks on Wall Street.Some investors tend to avoid these names entirely. While nominal prices typically don't matter (there's little difference between a $50 stock and a $500 stock), stocks under $10 are different. They often face some sort of difficulty, such as weak fundamentals or overwhelming headwinds. Also, institutional buyers such as pensions and hedge funds often won't buy stocks that are cheaper than $10, and they really become sparse under the $5 mark. Thus, these companies miss out on the steadiness that accompanies institutional ownership.But other investors love cheap stocks. In many cases, they see opportunity in these often battered shares, and some people simply prefer to buy their stocks in "lots" (typically 100 shares at a time) - something that's a little more difficult to do with the triple- and quadruple-digit crowd.The reality is, low-priced stocks are a mix of high-return opportunity but also high risk. The crazy volatility introduced by the coronavirus outbreak certainly doesn't help. Further complicating things is that many of them are largely ignored by the media, making information difficult to come by. So if you are going to take a moonshot, take a cue from the pros that routinely cover these companies.Here are seven of the best cheap stocks under $7. Using TipRanks' Stock Screener tool, we identified seven low-priced stocks that still have decent Wall Street analyst coverage and extremely bullish sentiment. Note that every one of these stocks still comes with colossal risk. But if you're looking to get aggressive and buy cheap on dips, the pros think each of these can offer some promise. SEE ALSO: 13 Super Small-Cap Stocks to Buy for 2020 and Beyond
PRINCETON, N.J., Feb. 25, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq.
Agile Therapeutics (AGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...
Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering.
Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company’s Lead Product Candidate, Receives FDA Approval.
Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
Agile Therapeutics Inc (NASDAQ: AGRX) shares are advancing Tuesday after the company announced clinching of a term loan facility. The micro-cap biotech that focuses on women's health said late Monday it has finalized a senior secured term loan credit facility with Perceptive Advisors to provide it funding up to $35 million. The facility will disburse term loans in three tranches.
Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit facility with Perceptive Advisors to provide Agile with up to $35 million through term loans in three tranches. $5 million was funded today after the satisfaction of customary closing conditions, $15 million will be available if Twirla® is approved by the U.S. Food and Drug Administration (“FDA”), and $15 million will be available upon the achievement of certain revenue milestones.
When searching for big rewards, look no further than biotech stocks.Just be prepared for big risk, too.Biotechs offer gobs of price potential. That's because unlike many companies that can slowly but steadily build up their businesses over time, the survival of biotechnology companies (especially early on) hinges on just a few trials of their developing treatments. Eventual approval of the drug means life-sustaining revenues for the company, so positive trial news can send shares skyrocketing. Setbacks, however, can spark an exodus.While it's impossible for regular investors to gauge what's going on in testing labs, you can give yourself a small leg up by paying attention to the analysts who cover the biotechnology industry. If you find a stock that's mostly surrounded by bulls, that might be a signal that something rewarding is around the bend.Here are five biotech stocks that have a "Strong Buy" consensus analyst rating and have potential catalysts right around the corner. We've used TipRanks' Smart Score system to identify this health-care short list. Also remember that biotechnology stocks come with a considerable amount of risk, and that sharp drops are not uncommon. Consider using only a small allocation from the portion of your portfolio dedicated to aggressive investments. SEE ALSO: 10 High-Quality, High-Growth Stocks to Buy
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold
Since we do expect at least short-term volatility, low-beta stocks are the best choice as they are less correlated to the index and thus tend to be less volatile.
PRINCETON, N.J., Jan. 06, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the company will present at the 38th Annual J.P..
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...
PRINCETON, N.J., Jan. 02, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Kimberly Whelan as Vice President of.
PRINCETON, N.J., Dec. 19, 2019 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has scheduled a company presentation at Biotech.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]